Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AMGEN INCAMGN · Entity 2832 | Acting CFO | June 30, 2014 | July 02, 2014 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AMGEN INC
Report date June 30, 2014 · Filed July 02, 2014
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 39,177 |
Reported balance
After 2014-06-30 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2014-06-30 · Tax withholding · Disposed 1,919 · Balance 39,177 F1: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans, approximately: 508 RSUs which vest in one installment on 4/25/2015; 804 RSUs which vest in two annual installments of 396 on 4/27/2015 and 408 on 4/27/2016; 780 RSUs which vest in two equal installments of 257 each on 4/26/2015 and 4/26/2016 and one installment of 266 on 4/27/2017; 4,203 RSUs which vest on 6/30/2015; and 628 RSUs which vest in two equal installments of 207 each on 4/25/2016 and 4/25/2017 and one installment of 214 on 4/25/2018. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2: These shares include approximately 99 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share interest. |
| Common StockSEC Table I · non-derivative | Indirect401(k) Plan | 184.44 |
Reported balance
Holding disclosure · report date 2014-06-30 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 184.44 F3: These are shares acquired under the Company's 401(k) Plan and represent interests in the Company's stock fund as of this filing. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans, approximately: 508 RSUs which vest in one installment on 4/25/2015; 804 RSUs which vest in two annual installments of 396 on 4/27/2015 and 408 on 4/27/2016; 780 RSUs which vest in two equal installments of 257 each on 4/26/2015 and 4/26/2016 and one installment of 266 on 4/27/2017; 4,203 RSUs which vest on 6/30/2015; and 628 RSUs which vest in two equal installments of 207 each on 4/25/2016 and 4/25/2017 and one installment of 214 on 4/25/2018. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
F2: These shares include approximately 99 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share interest.
F3: These are shares acquired under the Company's 401(k) Plan and represent interests in the Company's stock fund as of this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 03, 2006 Filed Apr 5, 2006 22:08 UTC | AMGEN INC AMGN · Entity 2832 | GrantNQSO (Right to Buy) · Derivative | 8,109 | $0.00 Strike: $71.88 | $0.00 |
DisclosureSEC source: 0001181431-06-022573 · rrd113469.xml · derivative · entry 4 Michael A Kelly · CIK 0001335311 · VP Corp Plng & Control & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,109 Underlying: Common Stock · 8,109 shares Expires 2013-04-03 F1 · price: Right to buy granted under the Company's Amended and Restated 1991 Equity Incentive Plan. F2 · derivative.exercise_date: The option becomes exercisable annually as follows: 2,375 shares on April 3, 2007; 2,375 shares on April 3, 2008; 2,375 shares on April 3, 2009 and 984 shares on April 3, 2010. Read SEC document |
| April 03, 2006 Filed Apr 5, 2006 22:08 UTC | AMGEN INC AMGN · Entity 2832 | GrantISO (Right to Buy) · Derivative | 1,391 | $0.00 Strike: $71.88 | $0.00 |
DisclosureSEC source: 0001181431-06-022573 · rrd113469.xml · derivative · entry 3 Michael A Kelly · CIK 0001335311 · VP Corp Plng & Control & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,391 Underlying: Common Stock · 1,391 shares Expires 2013-04-03 F1 · price: Right to buy granted under the Company's Amended and Restated 1991 Equity Incentive Plan. Read SEC document |
| March 02, 2006 Filed Feb 12, 2007 21:42 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 423 | $76.47 | $32,346.81 |
DisclosureSEC source: 0001181431-07-010581 · rrd146764.xml · nonDerivative · entry 1 Michael A Kelly · CIK 0001335311 · VP Corp Plng & Control & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,625 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.